The short duration of eye drops is a drawback of glaucoma treatment with eye drops. Eye drops are delivered 1-4 times daily which leads to poor treatment compliance of less than 50%. Under-treatment leads to poor eye pressure control, damage in the retina and optic nerve, and irreversible gradual loss of vision. The previous Academy of Finland project results show that melanin-binding carbonic anhydrase inhibitors have prolonged ocular retention and pressure reduction even two weeks after the instillation of a single eye drop. This project aims to develop optimal compounds with an even longer duration of action within the acquired intellectual property rights. The project will generate proof-of-concept for long-acting glaucoma medication that will be applied to the eye once per month as an eye drop. The project involves also the development of a utilization path including FDA consultation, regulatory strategy, and acquiring translational funding.

2025

2026